Dr. Nameeta Shah

Neuro-Oncology Program

Dr. Nameeta Shah, Ph.D

Dr.Nameeta Shah is a Principal investigator of the Neuro Oncology Program, at Mazumdar Shaw Center for Translational Research (MSCTR), Narayana Health, Bangalore. She received her B.E from Gujarat University, India and M.Tech degree in Computer Science and Engineering from Indian Institute of Technology, Kanpur. She obtained her Ph.D. at University of California, Davis in 2006. Her Ph.D. thesis, “Integrated visualization and computational methods to develop a system to infer gene regulation from large-scale genomics data” led to her interest in cancer research. She received her postdoctoral research experience at Michigan Center for Translational Pathology, Ann Arbor. The focus of her work was high throughput screening of gene fusions using large scale genomics and Fluorescent In Situ Hybridization (FISH) data which led to identification of ETV5 fusions in prostate cancer. She worked as a bioinformatics scientist for brain tumor research lab in USA for seven years where she established the computational infrastructure, and clinical and genomic databases. During that period,Dr.Nameeta led the Ivy Glioblastoma Atlas Project effort from Swedish Neuroscience Institute in collaboration with the team at Allen Institute for Brain Science, Seattle, WA, USA.With her extensive experience in brain tumor research, she is working towards expanding the neuro oncology research program at MSCTR for improved glioma patient care.

Research Interests

  • Gliomas and specifically glioblastoma (GBM), grade IV brain tumors are highly heterogeneous. As a result effective treatment options for these patients are still in the waiting.Her recent work on GBM reportsthat molecular signatures of anatomic features delineated histologically are highly conserved across patientsand reflect the biological processes, pathways, cell types and microenvironment relevant to each feature. Itis therefore extremely important to develop clinically feasible biomarkers that take in to account intratumorheterogeneity, are representative of the whole tumor and capture multiple parametersrepresented by anatomic features such as tumor cells, blood vessels, immune cells, etc. Also, the current cell culture models do not sufficiently reflect the disease in the patient. It is important to better understand GBM microenvironment and develop alternate 3D models that best reflect the disease and can be used for identification of better therapeutics.


  • 1. Puchalski RB, Shah N, Miller J, Dalley R, Nomura SR, Yoon J-G, et al. An anatomic transcriptional atlas of human glioblastoma. Science. American Association for the Advancement of Science; 2018 May 11; 360(6389):660–3. First author, corresponding author.
  • 2. Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N, et al. Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma. Clin Cancer Res. 2018 Aug 31.
  • 3. Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, et al. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns? Neuroradiology. 2018 Oct 10;60(10):1043–51.
  • 4. Jayaram S, Balakrishnan L, Singh M, Zabihi A, Ganesh RA, Mangalaparthi KK, et al. Identification of a Novel Splice Variant of Neural Cell Adhesion Molecule in Glioblastoma Through Proteogenomics Analysis. Omi A J Integr Biol. 2018 Jun 1;22(6):437–48. Corresponding author.
  • 5. Sirdeshmukh R, Jayaram S, Gupta MK, Sonpatki P, Singh M, Ganesh RA, et al. Integration of Transcriptomic and Proteomic Data for Disease Insights. In Humana Press. p. 325–56. Corresponding author.
  • 6. Kaverina N, Borovjagin A V., Kadagidze Z, Baryshnikov A, Baryshnikova M, Malin D, et al. Astrocytes promote progression of breast cancer metastases to the brain via a KISS1-mediated autophagy. Autophagy. 2017 Nov 2;13(11):1905–23.
  • 7. Ghosh D, Funk CC, Caballero J, Shah N, Rouleau K, Earls JC, et al. A Cell-Surface Membrane Protein Signature for Glioblastoma. Cell Syst. Cell Press; 2017 May 24;4(5):516–529.
  • 8. Schroeder B, Shah N, Rostad S, McCullough B, Aguedan B, Foltz G, et al. Genetic investigation of multicentric glioblastoma multiforme: case report. J Neurosurg. American Association of Neurological Surgeons; 2016 May 16;124(5):1353–8. First author.
  • 9. Ulasov I, Borovjagin A V., Kaverina N, Schroeder B, Shah N, Lin B, et al. MT1-MMP silencing by an shRNA-armed glioma-targeted conditionally replicative adenovirus (CRAd) improves its anti-glioma efficacy in vitro and in vivo. Cancer Lett. Elsevier; 2015 Sep 1;365(2):240–50.
  • 10. Ulasov I V., Shah N, Kaverina N V., Lee H, Lin B, Lieber A, et al. Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy. Oncotarget. 2015 Feb 28;6(6):3977–87.
  • 11. Shah N, Schroeder B, Cobbs C. MGMT methylation in glioblastoma: tale of the tail. Neuro Oncol. Oxford University Press; 2015 Jan;17(1):167–8. First author.
  • 12. Shah N, Lankerovich M, Lee H, Yoon J-G, Schroeder B, Foltz G. Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. BMC Genomics. 2013 Nov 22;14(1):818.
  • 13. Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon J-G, et al. Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM. Jones C, editor. PLoS One. Public Library of Science; 2011 Jan 7 ;6(1):e16146. First author, corresponding author.
  • 14. Panchalingam K, Paramchuk W, Hothi P, Shah N, Hood L, Foltz G, et al. Large-Scale Production of Human Glioblastoma-Derived Cancer Stem Cell Tissue in Suspension Bioreactors to Facilitate the Development of Novel Oncolytic Therapeutics.
  • 15. Panchalingam KM, Paramchuk WJ, Chiang C-YK, Shah N, Madan A, Hood L, et al. Bioprocessing of Human Glioblastoma Brain Cancer Tissue. Tissue Eng Part A. 2010 Apr;16(4):1169–77.